Malaria and HIV, two of the world’s most deadly diseases, are widespread, but their distribution overlaps greatly in sub-Saharan Africa. Consequently, malaria and HIV coinfection (MHC) is common in the region. In this paper, pertinent publications on the prevalence, impact, and treatment strategie...s of MHC obtained by searching major electronic databases (PubMed, PubMed Central, Google Scholar, ScienceDirect, and Scopus) were reviewed, and it was found that the prevalence of MHC in SSA was 0.7%–47.5% overall. Prevalence was 0.7%–47.5% in nonpregnant adults, 1.2%–27.8% in children, and 0.94%–37% in pregnant women. MHC was associated with an increased frequency of clinical parasitemia and severe malaria, increased parasite and viral load, and impaired immunity to malaria in nonpregnant adults, children, and pregnant women, increased in placental malaria and related outcomes in pregnant women, and impaired antimalarial drug efficacy in nonpregnant adults and pregnant women. Although a few cases of adverse events have been reported in coinfected patients receiving antimalarial and antiretroviral drugs concurrently, available data are very limited and have not prompted major revision in treatment guidelines for both diseases. Artemisinin-based combination therapy and cotrimoxazole are currently the recommended drugs for treatment and prevention of malaria in HIV-infected children and adults. However, concurrent administration of cotrimoxazole and sulfadoxine–pyrimethamine in HIV-infected pregnant women is not recommended, because of high risk of sulfonamide toxicity. Further research is needed to enhance our understanding of the impact of malaria on HIV, drug–drug interactions in patients receiving antimalarials and antiretroviral drugs concomitantly, and the development of newer, safer, and more cost-effective drugs and vaccines to prevent malaria in HIV-infected pregnant women.
more
The document "Prevansyon kont Diare" provides guidance on preventing and managing diarrhea. It explains that diarrhea, caused by pathogens like viruses, bacteria, and parasites, can lead to severe dehydration if untreated. Symptoms include vomiting, fever, and loss of appetite, with severe cases req...uiring urgent medical care.
To prevent diarrhea, the document emphasizes using treated or boiled water, washing hands with soap, cooking food thoroughly, and cleaning fruits and vegetables with safe water. It also provides a recipe for Oral Rehydration Solution (ORS) to combat dehydration: mix 1 liter of boiled or treated water with 8 teaspoons of sugar, 1 teaspoon of salt, and a pinch of baking soda. This solution should be consumed while seeking medical attention.
The document serves as an educational resource to promote hygiene and provide simple, effective solutions for preventing and managing diarrhea.
more
The technical note from the Global Task Force on Cholera Control (GTFCC) examines the risks and benefits of vaccinating pregnant women with WHO-prequalified oral cholera vaccines (OCVs) during mass vaccination campaigns. It highlights that three WHO-approved vaccines (Dukoral®, Shanchol™, and Euv...ichol®) offer sustained protection and a strong safety profile.
While these vaccines are not explicitly contraindicated for pregnant women, there is limited clinical data on their use during pregnancy. However, studies indicate that pregnant women with cholera face higher risks of fetal loss, stillbirth, and complications, especially if they experience severe dehydration. Some evidence suggests that vaccination can reduce cholera incidence in pregnant women and indirectly protect infants.
Although no controlled trials have focused on pregnant women, retrospective studies in Guinea and Zanzibar showed no significant increase in adverse pregnancy outcomes after OCV administration. The GTFCC concludes that the benefits of vaccination outweigh the risks, particularly in high-risk areas, and recommends including pregnant women in cholera vaccination campaigns while continuing to monitor safety data.
more
The PDF "Vamos proteger-nos da Cólera" provides comprehensive guidance on cholera prevention and response strategies, particularly for use in community health settings. It emphasizes the importance of safe water use by treating water with bleach, boiling it for at least 5 minutes, or using purifica...tion tablets like Aquatabs. Handwashing is highlighted as a key measure, especially after using the latrine, before preparing food, and before eating. Sanitation practices include using and maintaining clean latrines or, if unavailable, burying feces far from homes and water sources.
The document also addresses diarrhea treatment, recommending the preparation and use of Oral Rehydration Solution (ORS) with added zinc for effective recovery. It encourages breastfeeding for infants with diarrhea and stresses the importance of cooking food thoroughly, keeping it covered, and ensuring all utensils and surfaces are clean. Proper waste management, including the disposal of household waste, is highlighted to maintain a clean and safe environment.
In emergency situations, the guide advises seeking immediate medical attention for severe diarrhea and emphasizes the prompt burial of bodies during outbreaks to prevent contamination. Additionally, it provides visuals and strategies for community engagement, empowering health workers and communities to promote awareness and adopt effective cholera prevention measures.
more
The document presents a humanitarian snapshot from October 2017 highlighting the dire situation of children in Yemen. Over 11 million Yemeni children needed humanitarian assistance due to the conflict that began in March 2015. The report shows one child dying every 10 minutes from preventable causes..., with 386,000 suffering from severe acute malnutrition. The education system was near collapse with 2,531 schools damaged or repurposed, depriving 1.5 million children of education. More than 7,000 children had been killed or injured in the conflict, and child labor and early marriages were increasing as negative coping mechanisms. The report also notes that 55% of Yemen's 2.9 million displaced persons were children.
more
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19.
The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients.
This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines:
**High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%.
**Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%.
Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk.
Review of COVID-19 treatments for people with non-severe COVID-19
WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022.
If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead.
WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission.
For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol.
WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials.
The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials.
more
This handbook offers a simple framework of action for actors in local government, and in particular, health leaders such as Civil Surgeons (CSs) and Upazila Health and Family Planning Officers (UHFPQOs), to take ownership and leadership to combat COVID-19 at each district and upazila respectively, w...ith support and guidance from elected representatives and local administration, and through effective engagement of various segments of society including informal health care providers, religious leaders, journalists, police and law enforcement agencies, etc. The toolkit draws extensively from the experiences in Chapainawabganj, Savar and other areas and contains relevant best practises that have already proven effective in these places, which should be readily adaptable to various contexts.
It is important to note that while this framework has been developed in the context of COVID-19 and with related best practises, it is by no means limited to COVID-19 response. Indeed, the experience from Savar shows that the same approach has proven extremely effective in combating the dengue outbreak and the severe floods in 2020, and hence can be used to combat future public health emergencies in Bangladesh and other countries having similar contexts.
more
4th edition, Reference Manual
Цель настоящего документа - дать указания по очистке и дезинфекции поверхностей окружающей среды в контексте КОВИД-19. Настоящее руководство предназначено для раб...тников здравоохранения, специалистов в области общественного здравоохранения и органов здравоохранения, которые разрабатывают и осуществляют политику и стандартные оперативные процедуры (СОП) по очистке и дезинфекции поверхностей окружающей среды в контексте КОВИД-19.
Переведено с помощью www.DeepL.com/Translator (бесплатная версия)
more
Lancet Respir Med 2020Published OnlineMarch 20, 2020 https://doi.org/10.1016/S2213-2600(20)30134-
The document “Malaria Prophylaxis for Travellers: Guideline for Healthcare Workers” (2019) from Sri Lanka provides guidance for healthcare providers on preventing malaria among travelers to endemic areas.
It explains that since Sri Lanka was certified malaria-free in 2016, the main risk comes f...rom imported cases, mostly Sri Lankan travelers. The document emphasizes assessing travelers’ risk, advising on mosquito bite prevention, and prescribing appropriate chemoprophylaxis like chloroquine, mefloquine, atovaquone-proguanil, or doxycycline depending on destination and traveler profile.
It highlights that children, pregnant women, and immunocompromised individuals are particularly at risk, and stresses adherence to medications and protective measures. Special instructions are given on handling missed doses, long-term prophylaxis, and managing side effects. Overall, the guideline aims to maintain Sri Lanka’s malaria-free status by preventing reintroduction through well-informed traveler care.
more
Hey Facts about the disease
Mpox continues to affect people around the world. A new framework released today by WHO will guide health authorities, communities and other stakeholders in preventing and controlling mpox outbreaks, eliminating human-to-human transmission of the disease, and reducing spillover of the virus from ani...mals to humans.
Mpox is a viral illness caused by the monkeypox virus (MPXV). It can cause a painful rash, enlarged lymph nodes and fever. Most people fully recover, but some get very sick. The virus transmits from person to person through close, including sexual, contact. It also has animal reservoirs in east, central and west Africa, where spillovers from animals to humans can occasionally occur, sparking further outbreaks.
There are two different clades of the virus: clade I and clade II. Clade I outbreaks are deadlier than clade II outbreaks.
A major emergence of mpox linked to clade II began in 2017, and since 2022, has spread to all regions of the world. Between July 2022 and May 2023, the outbreak was declared a Public Health Emergency of International Concern. While that outbreak has largely subsided, cases and deaths continue to be reported today, illustrating that low-level transmission continues around the world.
Currently, there is also a major outbreak of clade I virus in the Democratic Republic of the Congo (DRC), where cases have been on the rise for decades. Since the beginning of the year, over 6500 cases and 345 deaths have been reported in the DRC. Almost half of these are among children under the age of 15 years.
The Strategic framework for enhancing prevention and control of mpox (2024–2027) provides a roadmap for health authorities, communities, and stakeholders worldwide to control mpox outbreaks in every context, advance mpox research and access to countermeasures, and to minimize zoonotic transmission.
more